Nable, G.J., Chang, A., Nable, E.G., Plautz, G., Fox, B.A.., Huang, L., and Shu, 
S, Immunotherapy of malignancy by in vivo gene transfer into tumors. Human Gene 
Therapy. 3:399-410, 1992. 
Nastala, C.L., Edington, H., Storkus, W., McKinney, T.G., Tahara, H., Brunda, 
M.J., Gately, M.K., Schreiber, R., and Lotze, M.T. Recombinant interleukin-12 
administration induces tumor regression in association with interferon-gamma and 
nitric oxide production, (submitted for publication) 
Naume, B., Gately, M. and Espevik, T. A comparative study of IL-12 (cytotoxic 
lymphocyte maturation factor)-, IL-12- and IL-7 induced effects on 
immunomagnetically purified CD56'*’ NK cells. J. Immunol., 148: 2429-2436, 1992. 
Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. Production of high-titer 
helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 
90: 8392-8396, 1993. 
Rosenberg SA, et al. 1989. Experience with the use of high-dose interleukin-2 
in the treatment of 652 cancer patients. Ann Surg 210:474-484. 
Rosenberg SA, et al. 1990. Gene transfer into humans: immunotherapy of patients 
with advanced melanoma using tumor infiltrating lymphocytes modified by 
retroviral gene transduction. N Engl J Med 323:570-578. 
Rubin JT and Lotze MT. 1992. Adoptive immunotherapy of cancer, in The biological 
approach to cancer treatment: biomodulation. MS Mitchell, ed. McGraw-Hill, (in 
press) . 
Scimbrook J, Fritsch EF, Maniatis T. Molecular Cloning, a laboratory manual (2nd 
editionj .New York: Cold Spring Harbor laboratory Press, 1989. 
Stern, A.S., Podlaski, F.J., Hulmes, J.D., Pan, Y.C.E., Quinn, P.M., Wolitz)cy, 
A.G., Familletti, P.C., Stremlo, D.L., Truitt, T., Chizzonite, R. and Gately, 
M.K. Purification to homogeneity and partial characterization of cytotoxic 
lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. 
Acad. Sci. USA, 87: 6808-6812, 1990. 
Tahara, H., Zeh, H.J.Z.III, Stokus, W.J., Pappo, I., Watkins, S.C., Gubler, U., 
Wolf, S.F., Robbins, P.D., Lotze, T.M. Fibroblasts genetically engineered to 
secrete interleukin-12 can suppress tumor growth and induce anti-tumor immunity 
to a murine melanoma in vivo. Cancer Research (in press) 
Tepper, R.I., Pattengal, P.K., Leder, P. Murine interleukin-4 displays potent 
anti-tumor activity in vivo. Cell, 57: 503-512, 1989. 
Wolf, S.F., Temple, P.A., Kobayashi M., Young E., Dicig M., Lowe, L., Dzialo R., 
Fitz L., Ferenz C., Hewick R.M., Kelleher K., Herrmann S.H., Clark S.C., Azzoni 
L., Chan S.H., Trinchieri G., and Perussia B. Cloning of cDNA for natural killer 
cell stimulatory factor, a heterodimeric cytokine with multiple biologic effect 
on T and natural killer cells. J. Immunol., 146: 3074-3081, 1991. 
Zitvogel L., Tahara, H., Gubler, U., Wolf, S.F., Gately M.K., Robbins, P.D. and 
Lotze, M.T. Construction and characterization of retroviral vectors expressing 
biologically active human IL-12. (submitted) 
[664] 
Recombinant DNA Research, Volume 19 
